# A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Study · id `cardio:ct-nct01493557` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01493557](<https://clinicaltrials.gov/study/NCT01493557>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01493557

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1067 participants.

## Technical summary

Registry record NCT01493557. Randomized; no masking; primary purpose prevention. Start 2011-12 (registry gives no type); primary completion 2014-07 (actual). Results posted on 2015-10-05.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 1067 participants (enrolled count; ClinicalTrials.gov record NCT01493557, source copy `cardio:ctgov-nct01493557-2015-10-05`, retrieved 2026-10-26)
- Start date: 2011-12 (registry gives no type) (ClinicalTrials.gov record NCT01493557, source copy `cardio:ctgov-nct01493557-2015-10-05`, retrieved 2026-10-26)
- Primary completion: 2014-07 (actual) (ClinicalTrials.gov record NCT01493557, source copy `cardio:ctgov-nct01493557-2015-10-05`, retrieved 2026-10-26)
- Completion: 2014-07 (actual) (ClinicalTrials.gov record NCT01493557, source copy `cardio:ctgov-nct01493557-2015-10-05`, retrieved 2026-10-26)
- Results first posted: 2015-10-05 (ClinicalTrials.gov record NCT01493557, source copy `cardio:ctgov-nct01493557-2015-10-05`, retrieved 2026-10-26)
- Countries: United States; Canada (ClinicalTrials.gov record NCT01493557, source copy `cardio:ctgov-nct01493557-2015-10-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01493557-2015-10-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
- Condition: Atrial Fibrillation
- Intervention (Drug): pantoprazole
- Intervention (Drug): Pradaxa (dabigatran etexilate)
- Intervention (Drug): Pradaxa, within 30 minutes after a meal
- Intervention (Drug): Pradaxa (dabigatran etexilate)
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

## Provenance

Content hash: 776f2598417cbc7a122302c618a0cacf500d86e5ee0db5950af9761469a15dc3
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
